Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma

Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma

NCT07093554 ·Status: RECRUITING ·Phase: PHASE1

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

NCT05238311 ·Status: NO_LONGER_AVAILABLE

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

NCT05050097 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

NCT05161598 ·Status: NO_LONGER_AVAILABLE

A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma

NCT05461209 ·Status: WITHDRAWN ·Phase: PHASE3

agenT-797 in Participants With Relapsed/Refractory Multiple Myeloma

NCT04754100 ·Status: COMPLETED ·Phase: PHASE1

A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT04776018 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT00065351 ·Status: COMPLETED ·Phase: PHASE2

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT05160584 ·Status: RECRUITING

Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients

NCT05463939 ·Status: APPROVED_FOR_MARKETING

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

NCT06285318 ·Status: RECRUITING

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

NCT05486975 ·Status: UNKNOWN ·Phase: EARLY_PHASE1

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

NCT06461988 ·Status: RECRUITING ·Phase: PHASE2

Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in Relapsed or Refractory Multiple Myeloma Patients

NCT03464916 ·Status: COMPLETED ·Phase: PHASE1

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441 ·Status: RECRUITING ·Phase: PHASE2

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

NCT06827860 ·Status: RECRUITING ·Phase: PHASE2

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma

NCT05007418 ·Status: RECRUITING ·Phase: PHASE1

Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

NCT03361748 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events

NCT06500884 ·Status: RECRUITING ·Phase: PHASE2

A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple Myeloma

NCT00742560 ·Status: COMPLETED ·Phase: PHASE2

Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

NCT03393273 ·Status: WITHDRAWN ·Phase: PHASE2

An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

NCT03601078 ·Status: COMPLETED ·Phase: PHASE2

Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients With Relapsed and Refractory Disease

NCT01410500 ·Status: APPROVED_FOR_MARKETING

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04586426 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT03215030 ·Status: TERMINATED ·Phase: PHASE1/PHASE2